ABIVAX Société Anonyme (ABVX.PA)
Develops immune-regulating drugs to treat inflammatory bowel diseases like ulcerative colitis.
108.80-0.04%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+77.8%
The outlook
ABVX.PA trades at 108.8, sitting well above its 50- and 200-day moving averages and positioned roughly mid-range in its 52-week span. Analyst consensus targets average around 27% above the current price. The overall sentiment leans bullish based on available data.
What’s behind the score
Price trendAbove its 50- & 200-day averages
52-week range63% of the way from its 52-week low to high
Price targetAvg target +27% vs current price
Analyst price target
~12-month · 6 analysts138.56average target+27.4% vs now
Now 108.80
Low 70.00High 180.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$9.48B
52-wk high
139.00
52-wk low
56.80
50-day avg
103.18
200-day avg
101.23
Trailing P/E
—